39,060 Bottle Eye Drop Recall Signals Sterility Supply Chain Risk

For supply chain and quality leaders, a 39,060-unit recall of Clear Eyes Maximum Itchy Eye Relief is not just a consumer safety note—it's a traceability and supplier-quality event. Prestige Consumer Healthcare initiated a voluntary Class II recall of a single lot distributed by Medtech Products, exposing how a sterility assurance deviation can propagate nationwide before detection. The recall's lot-specific data—2552A, expiration Sept. 30, 2027—gives supply chain teams a concrete test case in recall execution and reverse logistics.

Prestige Brand Holdings, doing business as Prestige Consumer Healthcare, has launched a voluntary recall of 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops after the U.S. Food and Drug Administration found a "lack of assurance of sterility" in a specific production lot. The recall, which began on July 29, 2026 and remains ongoing as of August 24, covers 15-milliliter bottles carrying lot code 2552A and an expiration date of September 30, 2027. The FDA has classified the action as a Class II recall, meaning exposure to the affected product may cause temporary or medically reversible adverse health consequences, with only a remote probability of serious harm.

“

In June 2026, the company completed the purchase of the Breathe Right brand and other assets from Foundation Consumer Healthcare for approximately $1.05 billion.

The affected eye drops were distributed by Medtech Products Inc., a Prestige Consumer Healthcare company, placing the event squarely within the consumer health over-the-counter pharmaceutical supply chain. Although 39,060 bottles is a modest volume compared with the nearly 12 million bottles of Rohto eye drops recalled earlier over sterility concerns, or the millions of prescription eye drops pulled nationwide, it is significant because ophthalmic products require absolute sterility. A single contaminated eye drop container can introduce pathogens directly to the eye, so regulatory thresholds are low and recall responses are aggressive.

For supply chain and manufacturing professionals, the phrase "lack of assurance of sterility" is a red flag that does not necessarily mean contamination was detected, but rather that the manufacturer could not prove the product met sterility standards. This can arise from deviations in aseptic processing, environmental monitoring excursions, sterilization validation gaps, or documentation failures. The recall of a single, clearly identified lot—2552A—demonstrates the value of lot-level traceability: without that code, the recall would have had to encompass a far larger volume or remain unresolved for years given the September 2027 expiration.

The timing of this recall comes as Prestige Consumer Healthcare is integrating a major acquisition. In June 2026, the company completed the purchase of the Breathe Right brand and other assets from Foundation Consumer Healthcare for approximately $1.05 billion. That transaction expands Prestige's portfolio of consumer health products, which already includes Dramamine, Luden's and Anacin. Acquisitions often surface new supplier relationships, contract manufacturing arrangements, and distribution channels that must be folded into a unified quality management system. A sterility assurance gap in an acquired or existing product line raises questions about whether quality oversight is scaling at the same pace as the company's portfolio.

The recall also illustrates the mechanics of reverse logistics in a regulated category. Once a recall is initiated, distributors like Medtech Products must notify downstream pharmacies, retailers, and wholesale partners to quarantine and return affected inventory. Consumers must be alerted through FDA and company communications to check their medicine cabinets for lot 2552A. Because the expiration date is more than a year away, the product could remain in consumer hands well into 2027, making recall effectiveness dependent on sustained public communication rather than a single announcement.